Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:PFNX NASDAQ:SNSE NASDAQ:TERN NASDAQ:TH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/ASNSESensei Biotherapeutics$14.15+2.1%$19.36$5.86▼$36.76$18.98M-0.2553,599 shs219,729 shsTERNTerns Pharmaceuticals$52.95$51.03$2.65▼$53.19$6.12B-0.374.84 million shs6.35 million shsTHTarget Hospitality$19.67-3.4%$17.47$5.97▼$20.85$1.97B1.471.02 million shs1.13 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePFNXPfenex0.00%0.00%0.00%0.00%0.00%SNSESensei Biotherapeutics0.00%0.00%-33.09%-59.34%+64.86%TERNTerns Pharmaceuticals0.00%0.00%0.00%+0.30%+1,319.57%THTarget Hospitality-0.39%-0.78%+17.28%+60.82%+185.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/ASNSESensei Biotherapeutics$14.15+2.1%$19.36$5.86▼$36.76$18.98M-0.2553,599 shs219,729 shsTERNTerns Pharmaceuticals$52.95$51.03$2.65▼$53.19$6.12B-0.374.84 million shs6.35 million shsTHTarget Hospitality$19.67-3.4%$17.47$5.97▼$20.85$1.97B1.471.02 million shs1.13 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePFNXPfenex0.00%0.00%0.00%0.00%0.00%SNSESensei Biotherapeutics0.00%0.00%-33.09%-59.34%+64.86%TERNTerns Pharmaceuticals0.00%0.00%0.00%+0.30%+1,319.57%THTarget Hospitality-0.39%-0.78%+17.28%+60.82%+185.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePFNXPfenex 0.00N/AN/AN/ASNSESensei Biotherapeutics 2.43Hold$48.00239.34% UpsideTERNTerns Pharmaceuticals 2.27Hold$55.144.13% UpsideTHTarget Hospitality 2.60Moderate Buy$19.33-1.69% DownsideCurrent Analyst Ratings BreakdownLatest TH, PFNX, TERN, and SNSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026THTarget Hospitality Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/11/2026SNSESensei Biotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.006/4/2026SNSESensei Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/1/2026THTarget Hospitality Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$22.005/29/2026SNSESensei Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/28/2026SNSESensei Biotherapeutics Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$50.005/22/2026SNSESensei Biotherapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.005/13/2026THTarget Hospitality OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $21.004/27/2026TERNTerns Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$58.004/26/2026TERNTerns Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/24/2026SNSESensei Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPFNXPfenexN/AN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$14.74 per shareN/ATERNTerns PharmaceuticalsN/AN/AN/AN/A$9.70 per shareN/ATHTarget Hospitality$320.64M6.14$0.38 per share51.24$3.90 per share5.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePFNXPfenexN/AN/AN/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics-$21.08M-$142.72N/AN/AN/AN/A-83.59%-256.50%8/4/2026 (Estimated)TERNTerns Pharmaceuticals-$96.21M-$1.03N/AN/AN/AN/A-20.02%-19.37%N/ATHTarget Hospitality-$37.12M-$0.44N/A29.35N/A-13.47%-11.11%-8.13%8/6/2026 (Estimated)Latest TH, PFNX, TERN, and SNSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q4 2025SNSESensei Biotherapeutics-$0.62-$131.45-$130.83-$131.45N/AN/A5/11/2026Q1 2026THTarget Hospitality-$0.11-$0.13-$0.02-$0.13$73.20 million$72.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthPFNXPfenexN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ATHTarget HospitalityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPFNXPfenexN/AN/AN/ASNSESensei BiotherapeuticsN/A14.3914.39TERNTerns PharmaceuticalsN/A62.4162.41THTarget Hospitality0.080.850.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPFNXPfenexN/ASNSESensei Biotherapeutics10.50%TERNTerns Pharmaceuticals98.26%THTarget Hospitality32.40%Insider OwnershipCompanyInsider OwnershipPFNXPfenexN/ASNSESensei Biotherapeutics7.00%TERNTerns Pharmaceuticals1.50%THTarget Hospitality3.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePFNXPfenex7134.30 millionN/ANot OptionableSNSESensei Biotherapeutics401.34 million1.25 millionNot OptionableTERNTerns Pharmaceuticals40115.52 million113.79 millionNot OptionableTHTarget Hospitality820100.16 million96.36 millionNot OptionableTH, PFNX, TERN, and SNSE HeadlinesRecent News About These CompaniesTarget Hospitality (TH): Buy, sell, or hold post Q1 earnings?July 1 at 1:16 AM | msn.comTarget Hospitality Corp. (NASDAQ:TH) Given Consensus Rating of "Moderate Buy" by AnalystsJune 26, 2026 | americanbankingnews.comTarget Hospitality Secures Major Hyperscaler Data Center ContractJune 25, 2026 | theglobeandmail.comTop 10 mid-cap consumer discretionary stocks by momentum gradeJune 23, 2026 | msn.comTarget Hospitality Is Aiming At The Right Growth Path, But Fully PricedJune 5, 2026 | seekingalpha.comTarget Hospitality Announces Closing of Secondary Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesMay 29, 2026 | prnewswire.comTarget Hospitality Corp (TH) Shares Fall 6.1% -- GF Value Says Still OvervaluedMay 28, 2026 | gurufocus.comTarget Hospitality Announces Pricing of Secondary OfferingMay 28, 2026 | prnewswire.comTarget Hospitality Announces Launch of Secondary OfferingMay 27, 2026 | prnewswire.comConsumer discretionary - travel and vacation providers stocks Q1 highlights: Target Hospitality (NASDAQ:TH)May 20, 2026 | msn.comTarget Hospitality, Tapestry, and Movado Shares Are Falling, What You Need To KnowMay 16, 2026 | finance.yahoo.comTarget Hospitality Faces Growth Constraints Amid Capital Access and Funding ChallengesMay 14, 2026 | theglobeandmail.comTarget Hospitality (TH) price target increased by 28.79% to 21.68May 14, 2026 | msn.comTarget Hospitality Corp.May 14, 2026 | edition.cnn.comA Look At Target Hospitality (TH) Valuation After Strong Multi Year Share Price GainsMay 13, 2026 | finance.yahoo.comWhy are Target Hospitality (TH) shares soaring today?May 12, 2026 | msn.comTarget Hospitality (NASDAQ:TH) reports sales below analyst estimates in Q1 CY2026 earnings, but stock soars 6.2%May 12, 2026 | msn.comTarget Hospitality Corp. (TH) Q1 2026 Earnings Call TranscriptMay 11, 2026 | seekingalpha.comHere's What Key Metrics Tell Us About Target Hospitality (TH) Q1 EarningsMay 11, 2026 | zacks.comTarget Hospitality (TH) Reports Q1 Loss, Lags Revenue EstimatesMay 11, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 2026TH, PFNX, TERN, and SNSE Company DescriptionsPfenex NYSEAMERICAN:PFNX$12.75 0.00 (0.00%) As of 10/1/2020Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.Sensei Biotherapeutics NASDAQ:SNSE$14.14 +0.30 (+2.13%) Closing price 06/15/2026Extended Trading$14.14 0.00 (0.00%) As of 06/15/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.Terns Pharmaceuticals NASDAQ:TERNTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Target Hospitality NASDAQ:TH$19.66 -0.70 (-3.41%) As of 02:48 PM Eastern This is a fair market value price provided by Massive. Learn more.Target Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Comcast’s NBCUniversal Split Puts Broadband Back in Focus Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push 3 European Stocks to Carry Investors Through the Back Half of 2026 3 Charts That Could Change the Course of Summer Trading Short Squeeze Alert—Moderna Stock Surges on New Strategy 3 ETFs Offering Exposure to Latin America’s Stock Market Rally These 3 Dividend Stocks Could Boost Your Income This July Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
